UK markets closed

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4600-0.1700 (-3.67%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.6300
Open4.5700
Bid4.3100 x 1300
Ask5.3100 x 800
Day's range4.4500 - 4.5700
52-week range4.0700 - 12.5300
Volume37,812
Avg. volume39,128
Market cap595.74M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-4.6112
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.28
  • EQS Group

    MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters

    DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2022 MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte PetersTim Demuth, M.D., Ph.D., has more than 20 years of broad leade

  • Motley Fool

    MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript

    At this time, I would like to turn the conference over to Julia Neugebauer. My name is Julia Neugebauer, head of investor relations at MorphoSys, and it is my pleasure to welcome you to our half year 2022 financial results conference call. With me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.

  • EQS Group

    MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

    DGAP-News: MorphoSys AG / Key word(s): Half Year ResultsMorphoSys AG Reports Second Quarter and First Half 2022 Financial Results 03.08.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 3, 2022MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth Efficacy and safety d